From Glucose Control to Disease Strategy: What ADA 2026 Revealed About the Future of Diabetes Development
The American Diabetes Association (ADA) Scientific Sessions have long served as a barometer for where diabetes research is headed. This year’s meeting in New Orleans was no exception. Unlike previous years, however, ADA 2026 was not defined by a single breakthrough therapy or headline clinical trial. Instead, it revealed a broader shift in how diabetes is being understood and, consequently, how therapies may be developed in the future. [1,3]
Across scientific presentations, late-breaking studies, symposium discussions and guideline updates, a consistent message emerged: the future of diabetes may be shaped by a more comprehensive approach to disease management, prevention and modification rather than glucose control alone. ADA 2026 highlighted five shifts shaping the future of diabetes development: the evolution of next-generation incretin therapies, growing focus on cardiometabolic outcomes, increasing integration of technology and AI, advances in precision medicine, and emerging disease-modifying approaches. Together, these themes reflect a broader move toward long-term health outcomes, personalised care and more holistic management of diabetes and metabolic disease. [1,3]
1. Next-generation incretin therapies are evolving beyond weight loss
The continued momentum behind incretin-based therapies was impossible to ignore at ADA 2026. [4–7]
Several highly anticipated presentations focused on next-generation agents, including retatrutide, survodutide, CagriSema, orforglipron and elecoglipron [4–7]. These programmes highlighted industry efforts to build on the success of first-generation GLP-1 receptor agonists through oral formulations, dual- and triple-agonist mechanisms and alternative dosing approaches. For example, phase 3 data presented for retatrutide continued to highlight substantial weight-loss and cardiometabolic outcome potential, while multiple oral incretin programmes underscored the industry’s focus on improving convenience and expanding treatment options. [4–7]
Scientifically, this represents an important transition. The discussion is moving beyond whether incretin-based therapies can reduce weight and improve glycaemic control. The focus is increasingly shifting towards optimisation and differentiation. [4–7]
Researchers discussed opportunities to improve durability, simplify administration, preserve lean body mass, enhance metabolic outcomes and address broader disease burdens associated with obesity and type 2 diabetes. [4–6]
Strategic importance for sponsors
Differentiation is becoming increasingly important in obesity and diabetes development. Sponsors may need to demonstrate value beyond weight loss alone by generating evidence related to long-term metabolic health, adherence, body composition and broader clinical outcomes. [4–7]
2. A shift towards integrated cardiometabolic outcomes
Perhaps the most significant shift highlighted at ADA 2026 was the expanding definition of meaningful outcomes in diabetes. [1,2]
A recurring theme throughout ADA 2026 was the growing integration of cardiovascular, kidney and liver outcomes into diabetes management [1,2]. Rather than viewing these complications separately, several presentations reflected a broader cardiometabolic perspective.
Studies evaluating cardiovascular outcomes, chronic kidney disease, heart failure and metabolic dysfunction-associated steatotic liver disease (MASLD) reinforced the idea that treatment success may extend beyond HbA1c measurements alone. [1,2,8]
As therapies increasingly demonstrate effects across multiple organ systems, the development paradigm is expanding from glucose management towards more holistic health outcomes. [1,2]
Strategic importance for sponsors
The industry is moving from disease control towards risk reduction and long-term health optimisation.
Sponsors should consider whether development strategies adequately capture outcomes that are meaningful to regulators, healthcare providers, payers and patients. Broader evidence packages may become increasingly important as therapies demonstrate effects across multiple organ systems.
3. Technology is becoming part of the therapeutic strategy
Technology was one of the most visible themes at ADA 2026. The conference featured extensive discussion around continuous glucose monitoring (CGM), automated insulin delivery systems, AI-enabled care models, closed-loop technologies and next-generation monitoring platforms. [1,2]
Several presentations highlighted the expanding role of CGM in broader patient populations, alongside advances in fully closed-loop systems and multi-analyte monitoring approaches [9–12]. One of the most discussed studies was CONNECT, which reported improvements in HbA1c and time-in-range among people with type 2 diabetes not treated with insulin, supporting discussion around broader CGM adoption. [9–12]
Researchers also explored how connected devices and real-time data streams could support more personalised care pathways. Scientifically, this represents a shift from episodic monitoring towards continuous, data-driven disease management. [9–12]
Strategic importance for sponsors
Future diabetes care may increasingly combine drugs, devices, digital tools and real-time data rather than relying on pharmacological intervention alone.
The convergence of therapeutics, devices and digital technologies has implications for study design, endpoint selection and evidence generation. Technology integration—including digital tools, monitoring technologies, and AI-enabled insights—is becoming an increasingly important component of clinical development strategies and a key consideration in demonstrating differentiated value.
4. Advancing precision medicine in diabetes
Another notable theme throughout ADA 2026 was growing recognition that diabetes is not a single disease experienced uniformly across all patients.
ADA 2026 highlighted advances in precision medicine, biomarkers, prevention strategies and diabetes heterogeneity. [1,3] Discussions focused on identifying disease earlier, better defining patient subgroups and developing more targeted interventions.
This move away from a "one-size-fits-all" approach reflects an increasing appreciation of the complexity of diabetes. Researchers presented evidence supporting more precise definitions, prevention strategies and treatment pathways, while exploring how biomarkers and risk stratification may help improve patient outcomes. [1,3]
Strategic importance for sponsors
Future diabetes development may be driven less by broad population approaches and more by patient segmentation and earlier intervention.
Precision-focused development programmes may become increasingly important for identifying responsive patient populations, strengthening evidence generation, and differentiating therapies in a crowded market.
5. The industry is looking beyond management towards disease-modifying approaches
Although still emerging, disease modification represented one of the most forward-looking discussions at ADA 2026. [1,3,13]
Among the conference's featured themes were beta-cell replacement, regenerative medicine and immune-based therapies aimed at achieving long-term remission or potentially curing diabetes. ADA identified these approaches as key areas of future innovation, while conference programming highlighted advances in stem cell-derived beta-cell therapies and other disease-modifying strategies. [1,3,13] Although these approaches remain relatively early compared with established diabetes therapies, they represent an important area of ongoing innovation.
Rather than continuously managing disease progression, the focus is increasingly turning towards restoring biological function, preserving beta-cell health and altering disease trajectories altogether. [1,3]
Strategic importance for sponsors
The long-term direction of diabetes research extends beyond better management towards prevention, remission and disease modification.
Advanced therapies may bring new development considerations, including patient selection, manufacturing complexity, long-term follow-up requirements and novel efficacy measures. These programmes may also create opportunities for significant differentiation in a rapidly evolving market. [1,3]
The bottom line: ADA 2026 redefined what progress looks like
If there was a unifying message from ADA 2026, it was that progress in diabetes is being viewed through a broader lens. Across obesity, cardiometabolic health, precision medicine, technology-enabled care and disease-modifying science, the discussions extended beyond glycaemic control alone and highlighted the increasingly interconnected nature of diabetes management. [1,3]
For sponsors, the conversation is no longer centered solely on demonstrating efficacy. Differentiation may increasingly be shaped by the ability to generate meaningful evidence, address patient variability, demonstrate value across the care continuum and contribute to long-term health outcomes. ADA 2026 underscored how rapidly the scientific and strategic landscape continues to evolve. As the clinical landscape evolves, organisations across the industry are evaluating how best to generate evidence that reflects the full complexity of diabetes and metabolic disease.
ADA 2026 reinforced that the future of diabetes development will likely be broader, more personalised and increasingly focused on long-term outcomes. [1–3] To learn more about clinical development considerations across diabetes, obesity and metabolic disease, visit Fortrea Diabetes & Endocrinology.
References
- American Diabetes Association. The American Diabetes Association Debuts the 2026 Scientific Sessions, Driving the Future of Diabetes Care. May 2026.
- ADA Meeting News. Trending Topics in Diabetes and Obesity Research and Care Highlight the 2026 Scientific Sessions Program. April 2026.
- American Diabetes Association. The American Diabetes Association Debuts the 2026 Scientific Sessions, Driving the Future of Diabetes Care. Press Release. May 27, 2026. New Orleans, LA. Available from: ADA Newsroom and 2026 Scientific Sessions Press Materials.
- HCPLive. ADA Scientific Sessions 2026 Preview: 6 Trials to Know.
- ADA Meeting News 2026 coverage of incretin and obesity therapies.
- American Diabetes Association. Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management. June 2026.
- Australian Diabetes Society. Highlights from ADA 2026 Scientific Sessions.
- ADA 2026 Scientific Sessions coverage highlighting cardiometabolic outcomes research.
- Pharmacy Times. ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use.
- MedTechDaily. ADA 2026 Scientific Sessions: Diabetes Technology Trends.
- Drug Delivery Business. The Biggest Diabetes Tech News Out of ADA 2026.
- diaTribe. Diabetes Technology Highlights From ADA 2026.
- ADA Meeting News. Welcome to New Orleans for the Scientific Sessions.